{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:42:49Z","timestamp":1770730969738,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06598-2","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:24:25Z","timestamp":1765373065000},"page":"6161-6168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can platelet to neutrophil ratio (PNR) serve as a viable alternative tool for monitoring sickle cell disease patients on hydroxyurea in low income countries?"],"prefix":"10.1007","volume":"104","author":[{"given":"Efobi Chilota","family":"Chibuife","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nri-Ezedi","family":"Chisom Adaobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Odini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habib Darbari","family":"Deepika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana-Bilkisu","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Campbell","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"6598_CR1","doi-asserted-by":"crossref","unstructured":"Steinberg MH (2016) Overview of sickle cell anemia pathophysiology. In: Costa FF (eds) Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International pp. 49\u201375","DOI":"10.1007\/978-3-319-06713-1_3"},{"key":"6598_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fimmu.2020.00454","volume":"11","author":"E Nader","year":"2020","unstructured":"Nader E, Romana M, Connes P (2020) The red blood cell\u2014inflammation vicious circle in sickle cell disease. Front Immunol 11:454","journal-title":"Front Immunol"},{"issue":"2","key":"6598_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cyto.2013.10.009","volume":"65","author":"ICJ Bandeira","year":"2014","unstructured":"Bandeira ICJ, Rocha LBS, Barbosa MC, Elias DBD, Querioz JAN, Freitas MVC et al (2014) Chronic inflammatory state in sickle cell anemia patients is associated with HBB*S haplotype. Cytokine 65(2):217\u201321","journal-title":"Cytokine"},{"issue":"2\u20133","key":"6598_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3233\/CH-189012","volume":"68","author":"N Conran","year":"2018","unstructured":"Conran N, Belcher JD (2018) Inflammation in sickle cell disease. Clin Hemorheol Microcirc 68(2\u20133):263\u201399","journal-title":"Clin Hemorheol Microcirc"},{"key":"6598_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/ajh.20059","volume":"76","author":"AFH Lum","year":"2004","unstructured":"Lum AFH, Wun T, Staunton D, Simon SI (2004) Inflammatory potential of neutrophil detected in sickle cell disease. Am J Haematol 76:126\u2013133","journal-title":"Am J Haematol"},{"issue":"3","key":"6598_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1600-0609.2012.01827.x","volume":"89","author":"Y Wali","year":"2012","unstructured":"Wali Y, Beshlawi I, Fawaz N (2012) Coexistence of sickle cell disease and severe congenital neutropenia: first impressions can be deceiving. Eur J Haematol 89(3):245\u201349","journal-title":"Eur J Haematol"},{"issue":"12","key":"6598_CR7","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1182\/blood.V97.12.3998","volume":"97","author":"AP Grigg","year":"2001","unstructured":"Grigg AP (2001) Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell\/beta + thalassemia. Blood 97(12):3998\u2013999","journal-title":"Blood"},{"key":"6598_CR8","doi-asserted-by":"crossref","unstructured":"Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110(6)","DOI":"10.1182\/blood-2006-12-061697"},{"key":"6598_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/B978-0-12-813456-6.00031-X","volume-title":"Platelets","author":"T Brzoska","year":"2019","unstructured":"Brzoska T, Kato GJ, Sundd P (2019) The role of platelets in sickle cell disease. In: Michelson AD (ed) Platelets, 4th edn. Academic Press, pp 563\u2013580","edition":"4"},{"key":"6598_CR10","doi-asserted-by":"crossref","unstructured":"Proen\u00e7a-Ferreira R, Brugnerotto AF, Garrido VT, Dominical VM, Vital DM, Ribeiro MdFR et al (2014) Endothelial activation by platelets from sickle cell anemia patients. PLoS One 9(2):e89012","DOI":"10.1371\/journal.pone.0089012"},{"issue":"1","key":"6598_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/09537104.2013.770136","volume":"25","author":"AL Frelinger III","year":"2014","unstructured":"Frelinger AL III, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD (2014) Platelet activation and inhibition in sickle cell disease (PAINS) study. Platelets 25(1):27\u201335","journal-title":"Platelets"},{"issue":"22","key":"6598_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood.V128.22.1295.1295","volume":"128","author":"MA Jimenez","year":"2016","unstructured":"Jimenez MA, Kato GJ, Sundd P (2016) Neutrophi-lplatelet aggregation enables vaso-occlusion in sickle cell disease. Blood 128(22):1295","journal-title":"Blood"},{"issue":"12","key":"6598_CR13","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","volume":"115","author":"E Voskaridou","year":"2010","unstructured":"Voskaridou E, Christoulas D, Bilalis A et al (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115(12):2354\u201363","journal-title":"Blood"},{"issue":"2","key":"6598_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pbc.22269","volume":"54","author":"BW Thompson","year":"2010","unstructured":"Thompson BW, Miller ST, Rogers ZR et al (2010) The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer 54(2):250\u20135","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"6598_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1590\/1516-3180.2013.1314467","volume":"131","author":"AC Silva-Pinto","year":"2013","unstructured":"Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FIR, Bassi SC, De Santis GC, Covas DT (2013) Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Sao Paulo Med J 131(4):238\u201343","journal-title":"Sao Paulo Med J"},{"key":"6598_CR16","doi-asserted-by":"publisher","first-page":"107602961982883","DOI":"10.1177\/1076029619828839","volume":"25","author":"AM Zahran","year":"2019","unstructured":"Zahran AM, Elsayh KI, Saad K et al (2019) Circulating microparticles in children with sickle cell anemia in a tertiary center in upper Egypt. Clin Appl Thromb Hemost 25:1076029619828839","journal-title":"Clin Appl Thromb Hemost"},{"issue":"12","key":"6598_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/ajh.24906","volume":"92","author":"JH Estepp","year":"2017","unstructured":"Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C et al (2017) A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol 92(12):1333\u201339","journal-title":"Am J Hematol"},{"key":"6598_CR18","doi-asserted-by":"crossref","unstructured":"Yamamoto-Furusho JK, Mendieta-Escalante EA (2020) Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with ulcerative colitis. PLoS One 15(4):e0231988","DOI":"10.1371\/journal.pone.0231988"},{"key":"6598_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jocn.2019.01.028","volume":"63","author":"P Jin","year":"2019","unstructured":"Jin P, Li X, Chen J et al (2019) Platelet-to-neutrophil ratio is a prognostic marker for 90-day outcome in acute ischemic stroke. J Clin Neurosci 63:110\u2013115","journal-title":"J Clin Neurosci"},{"key":"6598_CR20","first-page":"607","volume":"28","author":"M Kubat","year":"2022","unstructured":"Kubat M, \u015eeng\u00fcl S (2022) Value of neutrophil-to-platelet ratio and other indices in differentiating complicated acute appendicitis. Ulus Travma Acil Cerrahi Derg 28:607\u2013614","journal-title":"Ulus Travma Acil Cerrahi Derg"},{"issue":"5","key":"6598_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.4314\/ejhs.v33i5.12","volume":"33","author":"CC Efobi","year":"2023","unstructured":"Efobi CC, Nri-Ezedi CA, Madu CS, Ikediashi CC, Ejiofor OS, Ofiaeli I (2023) Neutrophil-lymphocyte, platelet-neutrophil, and platelet-lymphocyte ratios as indicators of sickle cell anaemia severity. Ethiop J Health Sci 33(5):821","journal-title":"Ethiop J Health Sci"},{"key":"6598_CR22","doi-asserted-by":"crossref","unstructured":"Asmaa MZ, Asmaa N, Khaled S, Helal FH, Alam-Eldin MA, Safwat MA (2020) Effect of hydroxyurea treatment on inflammatory markers among children with sickle cell disease. CATH 26:1\u20137","DOI":"10.1177\/1076029619895111"},{"issue":"10","key":"6598_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 312(10):1033\u201348","journal-title":"JAMA"},{"issue":"26","key":"6598_CR24","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","volume":"124","author":"TE Wong","year":"2014","unstructured":"Wong TE, Brandow AM, Lim W, Lottenberg R (2014) Update on the use of hydroxyurea therapy in sickle cell disease. Blood 124(26):3850\u20137","journal-title":"Blood"},{"key":"6598_CR25","doi-asserted-by":"crossref","unstructured":"Ryan N, Dike L, Ojo T et al (2020) Implementation of hydroxyurea therapy for sickle cell disease in resource-constrained settings: a systematic review. BMJ Open 10:e038685","DOI":"10.1136\/bmjopen-2020-038685"},{"key":"6598_CR26","doi-asserted-by":"crossref","unstructured":"Okocha EC, Gyamfi J, Ryan N, Babalola O, Etuk E et al (2022) Barriers to hydroxyurea use for sickle cell disease in Nigeria: a cross-sectional survey. Front Genet 12:765958","DOI":"10.3389\/fgene.2021.765958"},{"issue":"6","key":"6598_CR27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","volume":"103","author":"SA Zimmerman","year":"2004","unstructured":"Zimmerman SA, Schultz WH, Davis JS et al (2004) Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103(6):2039\u201345","journal-title":"Blood"},{"key":"6598_CR28","doi-asserted-by":"crossref","unstructured":"Alzahrani F, Albaz GF, AlSinan F et al (2021) Hydroxyurea use among children with sickle cell disease at King Abdulaziz University Hospital. Jeddah. Cureus 13(2):e13453","DOI":"10.7759\/cureus.13453"},{"key":"6598_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4103\/ijccm.IJCCM_49_18","volume":"22","author":"D Shome","year":"2018","unstructured":"Shome D, Jaradat A, Almahozi A et al (2018) The platelet count and its implications in sickle cell disease patients admitted for intensive care. Indian J Crit Care Med 22:585","journal-title":"Indian J Crit Care Med"},{"key":"6598_CR30","doi-asserted-by":"publisher","unstructured":"Keikhaei B, Yousefi H, Bahadoram M (2015) Hydroxyurea: clinical and hematological effects in patients with sickle cell anemia. Glob J Health Sci 8(3):252\u20136. https:\/\/doi.org\/10.5539\/gjhs.v8n3p252","DOI":"10.5539\/gjhs.v8n3p252"},{"issue":"1","key":"6598_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4314\/ahs.v17i1.31","volume":"17","author":"AS Adewoyin","year":"2017","unstructured":"Adewoyin AS, Oghuvwu OS, Awodu OA (2017) Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on usage pattern, effects, and compliance. Afr Health Sci 17(1):255\u201361","journal-title":"Afr Health Sci"},{"key":"6598_CR32","doi-asserted-by":"crossref","unstructured":"Chianumba RI, Ofakunrin AOD, Morrice J et al (2022) Outcome of hydroxyurea use in SCD and evaluation of patient perception in Nigeria. Front Genet 13:826132","DOI":"10.3389\/fgene.2022.826132"},{"issue":"4","key":"6598_CR33","first-page":"164","volume":"13","author":"O Oniyangi","year":"2019","unstructured":"Oniyangi O, Oyesakin AB, Ezeh GO et al (2019) The use of hydroxyurea in sickle cell disease: a single tertiary centre experience at the National Hospital, Abuja. Nigeria. S Afr J Child Health 13(4):164\u2013167","journal-title":"Nigeria. S Afr J Child Health"},{"key":"6598_CR34","doi-asserted-by":"crossref","unstructured":"Silva-Pinto AC, Angulo IL, Brunetta DM et al (2013) Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Sao Paulo Med J 131(4):238\u201343","DOI":"10.1590\/1516-3180.2013.1314467"},{"issue":"4","key":"6598_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.14444","volume":"176","author":"LH Pecker","year":"2017","unstructured":"Pecker LH, Schaefer BA, Luchtman-Jones L (2017) Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol 176(4):515\u2013526. https:\/\/doi.org\/10.1111\/bjh.14444","journal-title":"Br J Haematol"},{"issue":"13","key":"6598_CR36","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1182\/bloodadvances.2022009049","volume":"7","author":"WK Ghunney","year":"2023","unstructured":"Ghunney WK, Asare EV, Ayete-Nyampong JB, Oppong SA, Rodeghier M, DeBaun MR, Olayemi E (2023) Most adults with severe HbSC disease are not treated with hydroxyurea. Blood Adv 7(13):3312\u20133319. https:\/\/doi.org\/10.1182\/bloodadvances.2022009049","journal-title":"Blood Adv"},{"key":"6598_CR37","doi-asserted-by":"publisher","unstructured":"Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE (2016) Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol 91(2):238\u201342. https:\/\/doi.org\/10.1002\/ajh.24255","DOI":"10.1002\/ajh.24255"},{"issue":"5","key":"6598_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/00043426-200106000-00014","volume":"23","author":"MK Miller","year":"2001","unstructured":"Miller MK, Zimmerman SA, Schultz WH, Ware RE (2001) Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol 23(5):306\u20138. https:\/\/doi.org\/10.1097\/00043426-200106000-00014","journal-title":"J Pediatr Hematol Oncol Jun-Jul"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06598-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T19:02:57Z","timestamp":1770663777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06598-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6598"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06598-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained from the institutional review board (IRB) at Children's National Hospital, Washington DC, United States of America.. IRB number: Pro00010744","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this was a retrospective chart review using de-identified data, individual patient consent was waived by the IRB in accordance with ethical regulations and the principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}